TLR2 dimer‐specific ligands selectively activate protein kinase C isoforms in Leishmania infection

Arkajyoti Mukherjee,Sayoni Roy,Ashok Patidar,Neelam Bodhale,Jagneswar Dandapat,Bhaskar Saha,Arup Sarkar

DOI: https://doi.org/10.1111/imm.13373

2021-06-07

Immunology

Abstract:Of the thirteen Toll-Like Receptors (TLRs) in mice, TLR2 has a unique ability of forming heterodimers with TLR1 and TLR6. Such associations lead to selective cellular signaling and cellular responses such as cytokine expression. One of the signaling intermediates is Protein Kinase C (PKC); of which, eight isoforms are expressed in macrophages. Leishmania- a protozoan parasite that resides and replicates in macrophages- selectively modulates PKC-α, PKC-β, PKC-δ and PKC-ζ isoforms in macrophages. As TLR2 plays significant roles in Leishmania infection, we examined whether these PKC isoforms play selective roles in TLR2 signaling and TLR2-induced anti-leishmanial functions. We observed that the TLR2 ligands- Pam3CSK4 (TLR1/2), PGN (TLR2/2) and FSL (TLR2/6)- differentially phosphorylated and translocated PKC-α, PKC-β, PKC-δ and PKC-ζ isoforms to cell membrane in uninfected and L. major-infected macrophages. The PKC isoform-specific inhibitors differentially altered IL-10 and IL-12 expression, Th1 and Th2 responses and anti-leishmanial effects in macrophages and in BALB/c mice. While PKC isoforms' inhibitors had insignificant effects on the Pam3CSK4-induced anti-leishmanial functions, PGN-induced pro-leishmanial effects were enhanced by PKC-(α+β) inhibitors whereas PKC-(δ+ζ) inhibitors enhanced the anti-leishmanial effects of FSL. These results indicated that the ligand-induced TLR2 dimerization triggered differential dose-dependent and kinetic profiles of PKC isoforms activation and that selective targeting of PKC isoforms using their respective inhibitors in combination significantly modulated TLR2-induced anti-leishmanial functions. To the best of our knowledge, this is the first demonstration of TLR2-dimers signaling through PKC isoforms and TLR2-induced PKC isoforms-targeted anti-leishmanial therapy.

immunology